Highest-materiality recent filing
LifeMD Q2 revenue $47.3M, adjusted EBITDA loss $3.5M; revises FY2026 guidance
Revenue $47.3M within guidance; adjusted EBITDA loss $3.5M improved 21% sequentially but below guided range.
LifeMD will be the exclusive telehealth co-marketing partner for XYOSTED (testosterone enanthate) self-pay program.
LifeMD Q1 revenue $50.2M beats guidance; adds 42k subscribers, record GLP-1 signups
Revenue $50.2M vs guidance $48-49M; adj. EBITDA loss $4.5M in line.
LifeMD appoints new CFO, promotes CBO and CMO; outgoing CFO to advise
CFO Marc Benathen resigns effective March 31, 2026; will provide advisory services for 6–12 months at $38,117/month.
LifeMD FY2025 rev $194.1M (+25%), adj EBITDA $15.3M (+309%); guides to >$250M run-rate by Q4 2026
FY2025 revenue $194.1M (+25% YoY); adjusted EBITDA $15.3M (+309% YoY).
LifeMD closes $50M revolving credit facility with Citizens Bank, N.A.
Facility provides $30M committed plus $20M accordion; maturity January 2, 2029.
LifeMD Q3 revenue $60.2M (+13%), adj EBITDA $5.1M; paid off debt, sold WorkSimpli
Total revenue $60.2M (+13% YoY); adjusted EBITDA $5.1M (+20% YoY).
LifeMD delays Q3 earnings, expects late 10-Q filing due to $4.6M revenue recognition corrections
Q3 2025 earnings rescheduled to Nov 17, 2025; expects to file Form 12b-25 for late 10-Q.
LifeMD sells majority stake in WorkSimpli for $65M enterprise value; receives $22M cash at close
Sold 80% of WorkSimpli units to buyer group led by founder/CEO; enterprise value ~$65M.
LifeMD dismisses CBIZ CPAs, appoints PwC; cites material weaknesses in internal controls
On Aug 15, 2025, LifeMD dismissed CBIZ CPAs (appointed Apr 24, 2025) as auditor; no disagreements.
LifeMD Q2 revenue up 23% to $62.2M, adjusted EBITDA up 223% to $7.1M; revises FY2025 guidance
Total revenue $62.2M (+23% YoY), telehealth revenue $48.6M (+30%); telehealth adjusted EBITDA $3.4M (+560%).
LifeMD appoints Shayna Webb Dray as COO; promotes two other executives
Appointment of Shayna Webb Dray as COO effective March 27, 2025; base salary $400K, 100,000 RSUs with time and performance vesting.
LifeMD shareholders elect seven directors, ratify auditor at annual meeting
Elected directors: Justin Schreiber, Dr. Joseph DiTrolio, Roberto Simon, John Strawn, Dr. Joan LaRovere, William Febbo, Dr. Calum MacRae.
LifeMD Q1 revenue up 49% to $65.7M; first GAAP profit; raises FY 2025 guidance
Total revenue $65.7M (+49% YoY); telehealth revenue up 70% to $55.8M.
LifeMD acquires Optimal Human Health MD assets for 100k shares; launches women's health vertical
Acquired key assets from Optimal Human Health MD for 100,000 shares of common stock (50k at close, 50k at 1yr) plus earn-out.
LifeMD replaces auditor Marcum with CBIZ; cites material weaknesses in internal controls
Marcum LLP resigned as independent auditor on April 24, 2025; CBIZ CPAs P.C. appointed same day.
LifeMD Q4 revenue $64.3M (+43% YoY), adj EBITDA $9.0M; FY2025 rev guidance $265-275M
Q4 2024 revenue $64.3M (+43% YoY); telehealth revenue $49.9M (+60%); GAAP net loss narrowed to $0.9M from $4.5M.
LifeMD raises CEO Justin Schreiber's base salary to $500,000 effective Jan 1, 2025
Chairman and CEO Justin Schreiber's annual base salary increases from $300,000 to $500,000, effective January 1, 2025.
LifeMD board member Robert Jindal to resign effective Dec 31, 2024
Robert Jindal voluntarily resigned from LifeMD's board, effective December 31, 2024.
LifeMD director Naveen Bhatia resigns from board effective Oct 25, 2024
Naveen Bhatia voluntarily resigned from LifeMD's board of directors.
LifeMD stockholders approve 3M share increase in 2020 equity plan; all director nominees elected
Approved Third Amended and Restated 2020 Equity Plan, increasing share reserve by 3,000,000 shares (13,225,022 for, 8,347,423 against).
LifeMD appoints Dr. Calum MacRae, Harvard cardiologist, to board
Dr. MacRae appointed as independent director effective April 26, 2024.
LifeMD partners with Medifast, secures $20M investment for weight management collaboration
Medifast invests $20M total: $10M platform support payment and $10M purchase of 1,224,425 LifeMD shares at $8.1671/share.
LifeMD director Velge resigns; CEO Schreiber receives 100k share equity awards
Bertrand Velge resigned from LifeMD board effective Nov 8, 2023; no disagreement with company.
LifeMD furnishes investor presentation for August 2023; no specific new figures disclosed
Presentation expected to be used in meetings with investors, analysts, and others starting August 9, 2023.
LifeMD President Alex Mironov resigns to join Rothschild & Co.
Alex Mironov voluntarily resigned as President of LifeMD, effective July 28, 2023.
LifeMD cancels CFO's underwater options; grants 536,250 performance-vested restricted shares
CFO Marc Benathen's 200,000 stock options (strike $21.02) and 250,000 performance units cancelled.
LifeMD reports annual meeting results: directors elected, auditor ratified
At June 16 annual meeting, stockholders elected nine directors: Schreiber, Galluppi, Bhatia, DiTrolio, Simon, Strawn, Velge, Jindal, LaRovere.
LifeMD appoints William Febbo (OptimizeRx CEO) to Board; Galluppi resigns as director
Stefan Galluppi resigns from Board effective June 20, 2023; no disagreement; continues as Chief Innovation Officer.
LifeMD grants GC Eric Yecies 375,000 restricted shares with performance milestones
375,000 restricted shares granted; replaces 200,000 stock options ($7.55 strike) and 105,000 performance units cancelled.
LifeMD closes $40M senior secured credit facility with Avenue Capital; $15M drawn upfront
LifeMD closed $40M senior secured credit facility with Avenue Capital; initial $15M funded at closing.
Purchase price reduced by $250,000 to $3,670,000; all earn-out payments eliminated.
LifeMD appoints Dr. Joan LaRovere to Board; Kathleen E. Walsh resigns
Dr. Joan LaRovere appointed to LifeMD Board effective Feb 9, 2023; Board now 9 directors, 7 independent.
LifeMD appoints Kathleen E. Walsh to Board; grants 75,000 restricted shares and 37,500 stock options
Kathleen E. Walsh appointed to Board on Dec 15, 2022; she is President & CEO of Boston Medical Center.
LifeMD furnishes investor presentation materials; no material new information disclosed
Presentation dated November 2022 furnished as Exhibit 99.1 under Item 7.01.
LifeMD appoints former Louisiana Governor Bobby Jindal to board of directors
Appointment effective September 14, 2022; Jindal is the 55th Governor of Louisiana and current Operating Adviser at Ares Private Equity Group.
LifeMD dismisses Friedman LLP, engages Marcum LLP as auditor after Friedman-Marcum combination
Effective September 8, 2022, Audit Committee dismissed Friedman LLP and engaged Marcum LLP as independent auditor for FY2022.
LifeMD shareholders approve 1.5M share increase to 2020 equity plan, elect seven directors
Amendment to 2020 Equity Incentive Plan approved, increasing authorized shares by 1,500,000.
LifeMD furnishes February 2022 investor presentation; no material new information disclosed
Investor presentation dated February 2022 furnished under Regulation FD.
LifeMD subsidiary WorkSimpli acquires resume-building software assets for $4M
WorkSimpli Software, majority-owned by LifeMD, acquired resume-building software assets from East Fusion FZCO for $4M cash.
LifeMD appoints Maria Stan as Principal Accounting Officer, grants RSUs and PSUs
Maria Stan appointed as Controller and Principal Accounting Officer effective Feb 4, 2022.
LifeMD awards 75k RSUs and 250k PSUs to CFO; 37.5k RSUs and 105k PSUs to GC
CFO Marc Benathen receives 75k RSUs vesting over 2 years and 250k PSUs tied to revenue/EBITDA/stock price milestones.
LifeMD reports FY2021 preliminary revenue of $92.9M, +149% YoY; FY2022 guidance $142-148M
Preliminary Q4 2021 revenue $27.4M; FY2021 revenue $92.9M (149% YoY growth).
LifeMD furnishes investor presentation materials for January 2022
Presentation furnished under Item 7.01, expected use starting January 20, 2022.
LifeMD acquires allergy telehealth platform Cleared; total consideration up to $76.7M
Upfront $460k cash + $3.46M milestone payments + up to $72.8M earn-out based on $150M revenue.
Director Dr. Eleanor C. Mariano resigns from LifeMD board effective Nov 8, 2021
Dr. Eleanor C. Mariano voluntarily resigned from the LifeMD board of directors effective November 8, 2021.
LifeMD raises $21.4M from common, $32.9M from preferred stock offerings
3.83M common shares sold at $6.00/share; net proceeds ~$21.4M; $5M used to repay debt.
LifeMD furnishes investor presentation; no specific metrics in available text
Presentation materials dated September 27, 2021, furnished under Regulation FD.
LifeMD files investor presentation under Regulation FD; no material news disclosed
Furnishes investor presentation materials for use in meetings with investors and analysts commencing September 22, 2021.
Happy Walters resigned from LifeMD board on September 8, 2021.
Effective October 25, 2024, Naveen Bhatia voluntarily resigned from his position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).
On April 26, 2024, Calum MacRae was appointed to the Board of Directors.
Effective November 8, 2023, Bertrand Velge voluntarily resigned from his position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).
On July 28, 2023, Alex Mironov voluntarily resigned from his position as President of LifeMD, Inc. (the “Company”) in connection with his appointment as a Managing Director of Rothschild & Co.
On June 20, 2023, Stefan Galluppi resigned from the Board of Directors of LifeMD, Inc. (the "Company") effective immediately.
On June 20, 2023, William J. Febbo was appointed to the Board of Directors.
On February 9, 2023, LifeMD, Inc. (the “Company”) appointed Dr. Joan LaRovere to the board of directors (the “Board”) of the Company.
Effective February 9, 2023, Kathleen E. Walsh voluntarily resigned from her position as a member of the Board in connection with her appointment as the Secretary of the Executive Office of Health and Human Services for the Commonwealth of Massachusetts.
On December 15, 2022, LifeMD, Inc. (the “Company”) appointed Kathleen E. Walsh to the board of directors (the “Board”) of the Company.
On September 14, 2022, LifeMD, Inc. (the “Company”) appointed Robert Jindal to the board of directors (the “Board”) of the Company.
Effective February 4, 2022, Maria Stan was appointed as Controller and Principal Accounting Officer of LifeMD, Inc. (the “Company”).
Director Resignation Effective November 8, 2021, Dr. Eleanor C. Mariano voluntarily resigned from her position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).
Max materiality 0.80 · Median 0.50 · Most common event other_material